Cargando…

Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up

PURPOSE: To investigate the efficacy of early infliximab use and to follow the progress of pediatric cases of Crohn's disease for 3 years. METHODS: We reviewed the medical records of 28 pediatric patients who had been treated with infliximab for Crohn's disease. Eighteen patients (the ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yun Seok, Baek, Sang Hun, Kim, Mi Jin, Lee, Yoo Min, Lee, Yoon, Choe, Yon Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3746055/ https://www.ncbi.nlm.nih.gov/pubmed/24010094 http://dx.doi.org/10.5223/pghn.2012.15.4.243

Ejemplares similares

Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study
por: Kim, Yoon-Zi, et al.
Publicado: (2023)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn’s Disease with Infliximab Therapy
por: Kim, Mi Jin, et al.
Publicado: (2015)

Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn’s Disease Patients
por: Choi, Jaeyoung, et al.
Publicado: (2018)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
por: Choi, So Yoon, et al.
Publicado: (2023)

Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study
por: Song, Won Jae, et al.
Publicado: (2016)

Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn’s disease patients with secondary loss of response
por: Kim, Eun Sil, et al.
Publicado: (2023)

Clinical Course of Infliximab Treatment in Korean Pediatric Ulcerative Colitis Patients: A Single Center Experience
por: Kim, Jong Min, et al.
Publicado: (2014)

Change in the treatment strategy for pediatric Crohn's disease
por: Kim, Mi Jin, et al.
Publicado: (2010)

Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2017)

Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2019)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
por: Park, Jihye, et al.
Publicado: (2023)

Anti-Saccharomyces cerevisiae Antibody in Pediatric Crohn’s Disease Patients without Mucosal Healing Is a Useful Marker of Mucosal Damage
por: Kim, Mi Jin, et al.
Publicado: (2021)

Infliximab therapy in pediatric Crohn’s disease: a review
por: Parashette, Kalyan Ray, et al.
Publicado: (2010)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy
por: Kim, Mi Jin, et al.
Publicado: (2021)

Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target
por: Kang, Ben, et al.
Publicado: (2018)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
por: Aginbay, Aibar, et al.
Publicado: (2022)

Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
por: Kim, Nam Hee, et al.
Publicado: (2014)

Co-existence of relapsing polychondritis and Crohn disease treated successfully with infliximab
por: Jung, Hye-In, et al.
Publicado: (2020)

The Association Between Genetic Variants, Pharmacokinetics, and Infliximab Efficacy in Pediatric Patients With Crohn's Disease in China
por: Hu, Wenhui, et al.
Publicado: (2021)

Development of Spinal Tuberculosis in an Adolescent With Crohn's Disease After Infliximab Therapy: A Case Report With Literature Review
por: Jung, Jae Hoon, et al.
Publicado: (2022)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

Short-Term Outcome of Infliximab Therapy in Pediatric Crohn's Disease: A Single-Center Experience
por: Jung, Dai, et al.
Publicado: (2017)

Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab
por: Choi, Sujin, et al.
Publicado: (2021)

Henoch-Schönlein purpura associated with infliximab therapy for pediatric Crohn’s disease
por: Li, Xiaolu, et al.
Publicado: (2022)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
por: Kim, You Lim, et al.
Publicado: (2014)

Upper gastrointestinal tract involvement is more prevalent in Korean patients with pediatric Crohn’s disease than in European patients
por: Kim, Eun Sil, et al.
Publicado: (2020)

Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
por: Lee, Yoo Min, et al.
Publicado: (2022)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015)

Korean Children and Adolescents with Crohn's Disease Are More Likely to Present with Perianal Fistulizing Disease at Diagnosis Compared to Their European Counterparts
por: Kang, Ben, et al.
Publicado: (2020)

Pediatric Crohn’s disease with severe morbidity manifested by gastric outlet obstruction: two cases report and review of the literature
por: Kim, Eun Sil, et al.
Publicado: (2021)

Incidentally Detected Asymptomatic Perianal Abscess in an Adolescent during Crohn's Disease Diagnosis: Is Routine Pelvic Imaging Required in Korean Pediatric Patients at Diagnosis?
por: Um, Soo Hyun, et al.
Publicado: (2021)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn’s disease
por: Ma, Ye, et al.
Publicado: (2023)

Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study
por: Choi, Chang Hwan, et al.
Publicado: (2016)

Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn's Disease
por: Luo, Youyou, et al.
Publicado: (2017)

Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease
por: Wang, Yizhong, et al.
Publicado: (2021)

Discontinuation of Azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission
por: Jeong, Tae Jong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o1pdnqun1opakfqfvrp6qco4lo